MEDHERANT
Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel transdermal drug delivery platforms. Current patch technologies have limited drug loading capabilities, making them unviable for use with many pharmaceutical products that could benefit from transdermal delivery. Creams and gels on the other hand suffer from a lack of dose control that is critical for many drugs.
MEDHERANT
Industry:
Commercial Delivery Pharmaceutical
Founded:
2015-01-01
Address:
Coventry, Coventry, United Kingdom
Country:
United Kingdom
Website Url:
http://www.medherant.co.uk
Total Employee:
1+
Status:
Active
Contact:
+442476323060
Email Addresses:
[email protected]
Total Funding:
7.64 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Universal Analytics Apache Microsoft Exchange Online Office 365 Mail Google Maps
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Altamira Therapeutics
Altamira Therapeutics develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
OptiNose
OptiNose develops nasal drug delivery technologies and combined drug and device therapies.
Current Employees Featured
Founder
Investors List
Mercia Asset Management PLC
Mercia Asset Management PLC investment in Series A - Medherant
Innovate UK
Innovate UK investment in Grant - Medherant
Mercia Asset Management PLC
Mercia Asset Management PLC investment in Venture Round - Medherant
Mercia Asset Management PLC
Mercia Asset Management PLC investment in Seed Round - Medherant
Official Site Inspections
http://www.medherant.co.uk
- Host name: 165.9.205.92.host.secureserver.net
- IP address: 92.205.9.165
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Medherant"
Transdermal Drug Delivery TEPI Patches | Medherant
Medherant is creating a sustainable, next-generation transdermal drug delivery patch company that creates value for patients, partners and investors.See details»
About Us | Transdermal Drug Delivery Patches - Medherant
Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch ®. The company's lead project is a …See details»
Board & Management - Medherant
Dr Navdeep Bains is the Director of Research & Impact Services at the University of Warwick, one of the UK's leading universities. Warwick has an acknowledged reputation for excellence in research and innovation, and for the strength of its …See details»
Medherant - Crunchbase Company Profile & Funding
Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel transdermal drug delivery platforms. Current patch technologies …See details»
Medherant - Wikipedia
Medherant Ltd is a British pharmaceutical company, based in Coventry. The company develops over-the-counter (OTC) and prescription transdermal patches for drug delivery. See details»
Medherant: Game-changing drug delivery technology
Jun 13, 2023 · John Burt is CEO of Medherant – a West Midlands-based company developing innovative treatments using transdermal drug delivery technology. Formerly CEO of Abzena …See details»
Medherant Limited - LinkedIn
Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by...See details»
Medherant – innovative transdermal drug delivery moves to the …
Medherant has an exclusive worldwide licence to a novel, revolutionary, pressure sensitive adhesive developed by Bostik. The drug to be delivered is mixed with the adhesive.See details»
Medherant - VentureRadar
Website: http://www.medherant.co.uk/ Develops a testosterone replacement patch for menopausal women, featuring a proprietary adhesive and requiring bi-weekly changes. Plans …See details»
Medherant - Pharmaceutical Technology
Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel technologies for delivery of drugs via the skin using its world-leading expertise in bioadhesives and polymer …See details»
Contact Us - Medherant
Contact details Phone: +44 (0)24 7632 3060 Email: [email protected] Address: Medherant Limited The Venture Centre University of Warwick Science Park Sir William Lyons Road …See details»
Medherant Company Profile - Office Locations, Competitors ... - Craft
Medherant is a clinical-stage drug delivery company developing products for pain and CNS diseases. It provides a drug-in-adhesive transdermal delivery system, the TEPI Patch. The …See details»
Researchers create world's first ibuprofen pa | EurekAlert!
Dec 8, 2015 · Researchers at the University of Warwick have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World's first ever …See details»
Mercia invests £2.0 million in transdermal drug delivery specialist ...
COVENTRY, UK - May 21, 2019 - Medherant Limited ( Medherant ), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI …See details»
Business Model and Strategy - Medherant
Medherant is building a sustainable transdermal drug delivery company that generates value for patients, partners and investors by levering its unique TEPI Patch ® technology. Medherant …See details»
Medherant - Products, Competitors, Financials, Employees, …
Medherant is a clinical-stage company focused on developing innovative treatments in the pharmaceutical sector with its novel transdermal drug delivery technology. Use the CB Insights …See details»
Medherant Company Profile 2024: Valuation, Funding & Investors
Medherant is headquartered in Coventry, United Kingdom. What is the size of Medherant? Medherant has 21 total employees. What industry is Medherant in? Medherant’s primary …See details»
Our Products - Medherant
Medherant’s TEPI Patch ® is a new transdermal drug delivery system based on a novel adhesive which confers superior properties on the products. The TEPI Patch is thin, flexible, comfortable …See details»
Mercia invests £2.0 million in transdermal drug delivery specialist ...
Coventry, UK, 21st May 2019 / Sciad Newswire / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using …See details»
Medherant | VentureRadar
Website: http://www.medherant.co.uk/ Develops a testosterone replacement patch for menopausal women, featuring a proprietary adhesive and requiring bi-weekly changes. Plans …See details»